Ra Capital Management, L.P. X4 Pharmaceuticals, Inc Transaction History

Ra Capital Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$6.49 - $9.56 $3.48 Million - $5.13 Million	-536,962 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.41 - $7.4 $121,898 - $166,736	-22,532 Reduced 4.03%	536,962 $3.45 Million
Q2 2020 Aug 14, 2020	SELL	$7.98 - $10.44 $341,384 - $446,623	-42,780 Reduced 7.1%	559,494 $5.21 Million
Q1 2020 May 15, 2020	BUY	$6.03 - $11.01 $2 Million - $3.66 Million	331,982 Added 122.82%	602,274 $6.02 Million
Q4 2019 Feb 14, 2020	SELL	$9.93 - $14.33 $2.06 Million - $2.98 Million	-207,815 Reduced 43.47%	270,292 $2.89 Million
Q3 2019 Nov 14, 2019	SELL	$11.06 - $15.75 $4.24 Million - $6.04 Million	-383,286 Reduced 44.5%	478,107 $6.08 Million
Q2 2019 Aug 14, 2019	BUY	$12.57 - $21.67 $10.8 Million - $18.7 Million	861,393 New	861,393 $12.9 Million

99.6M

421K

80.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $21.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.